MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells

PloS One
Shuit-Mun WongHuei-Mei Huang

Abstract

Chronic myeloid leukemia (CML) is a clonal disorder of hematopoietic stem/progenitor cells that is caused by the Bcr-Abl oncoprotein. Clinical resistance to the Bcr-Abl inhibitor imatinib is a critical problem in treating CML. This study investigated the antitumor effect and mechanism of MPT0B169, a new antitubulin agent, in K562 CML cells and their derived imatinib-resistant cells, IMR2 and IMR3. IMR2 and IMR3 cells showed complete resistance to imatinib-induced growth inhibition and apoptosis. Resistance involved ERK1/2 overactivation and MDR1 overexpression. MPT0B169 inhibited the growth of K562, IMR2, and IMR3 cells in a dose- and time-dependent manner. MPT0B169 substantially inhibited the mRNA and protein levels of Bcr-Abl, followed by its downstream pathways including Akt, ERK1/2, and STAT3 in these cells. MPT0B169 treatment resulted in a decrease in the polymer form of tubulin according to Western blot analysis. It triggered cell cycle arrest at the G2/M phase before apoptosis, which was related to the upregulation of the mitotic marker MPM2 and the cyclin B1 level, and a change in the phosphorylation of Cdk1. MPT0B169 induced apoptosis in nonresistant and imatinib-resistant cells via a mitochondrion-mediated caspase pat...Continue Reading

References

May 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·F M DavisP N Rao
Jun 1, 1995·Journal of Cellular Biochemistry·K L King, J A Cidlowski
Apr 29, 1998·The Journal of Biological Chemistry·J G PastorinoJ L Farber
Nov 7, 1998·The Journal of Biological Chemistry·C D ScatenaJ A Pietenpol
Aug 30, 2001·Cell Death and Differentiation·S S SmailiR J Youle
Oct 25, 2003·Oncogene·Suresh V AmbudkarMichael M Gottesman
Apr 2, 2004·Nature Reviews. Cancer·Mary Ann Jordan, Leslie Wilson
Jul 19, 2005·Cancer Cell·Suzanne Cory, Jerry M Adams
Sep 15, 2007·Nature Reviews. Drug Discovery·Alfonso Quintás-CardamaJorge Cortes
Jun 21, 2008·Acta Haematologica·John M Goldman, Junia V Melo
Feb 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xianping ShiJingxuan Pan
Sep 17, 2010·Journal of Cell Science·Shawn B Bratton, Guy S Salvesen
Oct 5, 2010·Nature Reviews. Drug Discovery·Charles Dumontet, Mary Ann Jordan
Nov 27, 2010·Journal of Hematology & Oncology·Guoqing WeiDelong Liu
Dec 4, 2012·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Jun LeeXingguo Zhang
Oct 15, 2013·British Journal of Pharmacology·M J RoyG Lessene
Nov 22, 2013·International Journal of Clinical Oncology·Shinya KimuraKensuke Kojima
Dec 18, 2013·American Journal of Physiology. Cell Physiology·Wei-Hwa LeeHuei-Mei Huang
Mar 31, 2015·Annals of Hematology·Carmen FavaGiuseppe Saglio
Mar 31, 2015·Annals of Hematology·Michele BaccaraniGianantonio Rosti
Nov 30, 2015·Biochemistry. Biokhimii︠a︡·M A Savitskaya, G E Onishchenko

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis
X-ray
flow cytometry
PCR

Software Mentioned

Cellquest
ImageJ
ModFit LT

Related Concepts

Related Feeds

Apoptotic Caspases

Apoptotic caspases belong to the protease enzyme family and are known to play an essential role in inflammation and programmed cell death. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis